先瑞达医疗获药监局批准冠脉微导管注册
财中社1月21日电先瑞达医疗-B（06669）发布公告，宣布其冠状动脉微导管VERICOR-S2®的注册申请已获得中国国家药品监督管理局批准。该产品主要用于冠脉血管经皮介入手术中，能够有效引导导丝穿通狭窄血管病变部位，为更换导丝和传输生理盐水或造影剂提供通道。该微导管具有卓越的通过性、跟随性与推送性，能够在狭窄病变、迂曲与细小血管中顺利穿行。
公司计划在中国开展相关的营销活动，但也提醒股东及潜在投资者，最终的营销成功并不确定，因此在买卖公司股份时应谨慎行事。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10